Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status

Breast Cancer Research and Treatment

Volumn 147, Issue 1, 2014, Pages 185-191

  Prat, Aleix ^a   Cruz, Cristina ^a   Hoadley, Katherine A ^b   Díez, Orland ^a   Perou, Charles M ^b   Balmaña, Judith ^a  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Basal like; BRCA1; Breast cancer; Intrinsic subtype

Indexed keywords

DNA; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN; PROTEIN; PROTEIN P53; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; BASAL LIKE BREAST CANCER; BREAST CARCINOGENESIS; CANCER CLASSIFICATION; CANCER GENETICS; CANCER GRADING; CANCER PROGNOSIS; CHROMOSOME 22Q; CHROMOSOME 2Q; CHROMOSOME 3Q; CHROMOSOME 6P; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA METHYLATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENOME ANALYSIS; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROUS OVARY CARCINOMA; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; BASAL CELL CARCINOMA; BREAST TUMOR; CANCER STAGING; CHROMOSOME ABERRATION; CLASSIFICATION; DNA MICROARRAY; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENETICS; HUMAN CHROMOSOME; INFORMATION PROCESSING; METABOLISM; PATHOLOGY; PROGNOSIS;

BRCA1 PROTEIN; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; DATASETS AS TOPIC; DNA METHYLATION; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GERM-LINE MUTATION; HUMANS; MICRORNAS; NEOPLASM GRADING; NEOPLASM PROTEINS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906059059     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3056-x     Document Type: Article

References (30)

1. TCGA (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61-70
2. Prat A, Adamo B, Cheang MCU, Anders CK, Carey LA, Perou CM (2013) Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 18(2):123-133. doi:10.1634/theoncologist.2012-0397
3. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482-1485
4. Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, Ursin G (2011) Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol 29(33):4373-4380. doi:10.1200/jco.2010.33.6446
5. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8):2329-2334. doi:10.1158/1078-0432.ccr-06-1109
6. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn H-J (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. doi:10.1093/annonc/mdt303
7. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JHM, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123-134. doi:10.1056/NEJMoa0900212
8. Carey LA (2010) Targeted chemotherapy? platinum in BRCA1-dysfunctional breast cancer. J Clin Oncol 28(3):361-363. doi:10.1200/jco.2009.24.0838
9. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wiśniowski R, Siolek M, Dent R, Lubinski J, Narod S (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28(3):375-379. doi:10.1200/jco.2008.20.7019
10. Balmaña J, Domchek SM, Tutt A, Garber JE (2011) Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov. doi:10.1158/2159-8274.cd-11-0048
11. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C (2011) Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and non-carriers: a single-institution experience. J Clin Oncol 29(28):3739-3746. doi:10.1200/jco.2011.35.2682
12. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do K-A, Mills GB, Meric-Bernstam F (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082-1089. doi:10.1158/1078-0432.ccr-10-2560
13. Bayraktar S, Gutierrez-Barrera A, Liu D, Tasbas T, Akar U, Litton J, Lin E, Albarracin C, Meric-Bernstam F, Gonzalez-Angulo A, Hortobagyi G, Arun B (2011) Outcome of triplenegative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130(1):145-153. doi:10.1007/s10549-011-1711-z
14. Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK (2013) Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin Exp Metastasis 30(5):631-642. doi:10.1007/s10585-013-9567-8
15. Huzarski T, Byrski T, Gronwald J, Górski B, Domagała P, Cybulski C, Oszurek O, Szwiec M, Gugała K, Stawicka M, Morawiec Z, Mierzwa T, Janiszewska H, Kilar E, Marczyk E, Kozak-Klonowska B, Siołek M, Surdyka D, Wiśniowski R, Posmyk M, Sun P, Lubiński J, Narod SA (2013) Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol. doi:10.1200/jco.2012.45.3571
16. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121(7):2750-2767. doi:10.1172/jci45014
17. Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, Pietenpol JA (2012) TNBCtype: a subtyping tool for triple-negative breast cancer. Cancer Inform 11 (3284-CIN-TNBCtype:-A-Sub-typing-Tool-for-Triple-Negative-Breast-Cancer.pdf): 147-156. doi:10.4137/cin.s9983
18. Larsen MJ, Kruse TA, Tan Q, Lænkholm A-V, Bak M, Lykkesfeldt AE, Sørensen KP, TvO Hansen, Ejlertsen B, Gerdes A-M, Thomassen M (2013) Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by rna tumor profiling. PLoS ONE 8(5):e64268. doi:10.1371/journal.pone.0064268
19. TCGA (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615
20. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borre-sen- Dale A-L, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752
21. Beger C, Pierce LN, Krüger M, Marcusson EG, Robbins JM, Welcsh P, Welch PJ, Welte K, King M-C, Barber JR, Wong-Staal F (2001) Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc Natl Acad Sci 98(1):130-135. doi:10.1073/pnas.98.1.130
22. Deng C-X (2006) BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 34(5):1416-1426. doi:10.1093/nar/gkl010
23. von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, Kümmel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15(7):747-756. doi:10.1016/S1470-2045(14)70160-3
24. Sikov W, Berry D, Perou C, Singh B, Cirrincione C, Tolaney S, Kuzma C, Pluard T, Somlo G, Port E, Golshan M, Bellon J, Collyar D, Hahn O, Carey L, Hudis C, Winer E (2013) Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). San Antonio Breast Cancer Symposium S5-01
25. Byrski T, Dent R, Blecharz P, Foszczynska-Kloda M, Gronwald J, Huzarski T, Cybulski C, Marczyk E, Chrzan R, Eisen A, Lubinski J, Narod S (2012) Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 14(4):R110
26. Von Minckwitz G, Hahnen E, Fasching P, Hauke J, Schneeweiss A, Salat C, Rezai M, Blohmer J, Zahm D, Jackisch C, Gerber B, Klare P, Kummel S, Eidtmann H, Paepke S, Nekljudova V, Loibl S, Untch M, Schmutzler R, Groups aGaA-BS Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple negative breast cancer (TNBC)-Results from GeparSixto. Proc Am Soc Clin Oncol: a1005, 2014
27. Leong C-O, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW (2007) The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Investig 117(5):1370-1380. doi:10.1172/JCI30866
28. Birkbak NJ, Wang ZC, Kim J-Y, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL (2012) Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2(4):366-375. doi:10.1158/2159-8290.cd-11-0206
29. Isakoff S, He L, Mayer E, Goss P, Traina T, Carey L, Krag K, Liu M, Rugo H, Stearns V, Come S, Ryan P, Finkelstein D, Hartman A, Garber J, Timms K, Winer E, Ellisen L Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009. Proc Am Soc Clin Oncol: a1020, 2014
30. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160-1167. doi:10.1200/jco.2008.18.1370